Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Antibodies Studied
Download: Excel (XLSX), Comma-separated (CSV)
- 3 Antibodies
| HMS LINCS ID | Name | Alternative Names | Clone Name | LINCS ID | Resource Identification Initiative ID | Nominal Protein Target HMS LINCS ID(s) |
|---|---|---|---|---|---|---|
| 80076-1 | Trastuzumab | Herceptin; rhuMAb HER2 | huMAb4D5-8 | |||
| 80077-1 | Pertuzumab | Omnitag; Perjeta | rhuMAb2C4 | |||
| 80078-1 | Cetuximab | Erbitux |
- 3 Antibodies